BCL2 and acute myeloid leukemia: For LSD1, prioritize iadademstat + venetoclax ± HMA in unfit AML, with pharmacodynamic assays by week 2–3 to confirm enhancer rewiring and BCL-2 priming (Chatzilygeroudi et al., 2025).